Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats

Xiao-Yan Chu, Yukio Kato and Yuichi Sugiyama
Drug Metabolism and Disposition April 1999, 27 (4) 440-441;
Xiao-Yan Chu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukio Kato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuichi Sugiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In our previous work, we found that the biliary excretion of the carboxylate form of irinotecan, CPT-11, on rat bile canalicular membrane consists of two components, the low-affinity one being canalicular multispecific organic anion transporter (cMOAT). In the present study, we have investigated the high-affinity component by studying the uptake in canalicular membrane vesicles. The ATP-dependent uptake of the carboxylate form of CPT-11 was inhibited significantly by several substrates and/or modulators of P-glycoprotein, including PSC-833, verapamil, and cyclosporin A, at a substrate concentration of 5 μM, at which the high-affinity component is involved predominantly in CPT-11 transport. When the concentration of the carboxylate form of CPT-11 was 250 μM, at which the low-affinity component (cMOAT) is involved predominantly in its transport, the inhibitory effect of the above compounds was reduced greatly. Similarly, there was also much lower inhibition of the ATP-dependent uptake of S-(2,4-dinitrophenyl)-glutathione, a substrate of cMOAT, by the above compounds. Taurocholic acid, a substrate of canalicular bile acid transporter, failed to inhibit the uptake of CPT-11 at the substrate concentration of both 5 and 250 μM. These results suggest that P-glycoprotein may act as the high-affinity component in the biliary excretion of the carboxylate form of CPT-11 in rats.

Irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin (CPT-11)1 is a potent anticancer drug with a broad spectrum of antitumor activity (Slichenmyer et al., 1993). As a prodrug, CPT-11 is converted in vivo by carboxylesterase to its active metabolite, SN-38 (Kojima et al., 1993). The α-hydroxy-δ-lactone ring in CPT-11 and its metabolites are unstable, and conversion to the carboxylate form at physiological pH is easy (Fassberg and Stella, 1992). Biliary excretion is a major elimination pathway for CPT-11 and its metabolites (Kaneda and Yokokura, 1990). Our previous investigation using isolated rat canalicular membrane vesicles (CMVs) showed that two saturable transport components are involved in ATP-dependent uptake of the carboxylate form of CPT-11: canalicular multispecific organic anion transporter (cMOAT) is responsible as the low-affinity component (Km = 236 μM,Vmax = 1992 pmol/min/mg protein), whereas its high-affinity component (Km = 3.39 μM, Vmax = 115 pmol/min/mg protein) is governed by a transporter other than cMOAT, which is also expressed in Eisai hyperbilirubinemic rats with a genetic cMOAT deficiency (Chu et al., 1997b). Gupta et al. (1996) found that cyclosporin A (CsA) inhibits the biliary excretion of CPT-11 and its metabolites in rats. This suggests that one of the possible candidates for the high-affinity component of CPT-11 transport is P-glycoprotein (P-gp). However, CsA as well as other substrates and/or modulators of P-gp are potent inhibitors of not only P-gp, but also cMOAT and canalicular bile acid transporter. Böhme et al. (1993)reported that the inhibition constant (Ki) of CsA and (3′-oxo-4-butenyl-4-methyl-threoninel)-(Val2)-cyclosporin (PSC-833), the nonimmunosuppressive analog of CsA, for P-gp was one-half and 100 times smaller than that for cMOAT, respectively. Accordingly, in the present study, we investigated the effect of these compounds on the ATP-dependent uptake of the carboxylate form of CPT-11 by varying their concentrations. To assess the specificity of such an inhibitory effect, we also carried out control experiments to determine the effect of these compounds on the uptake ofS-(2,4-dinitrophenyl)-glutathione (DNP-SG), a substrate of cMOAT.

Experimental Procedures

Materials.

CPT-11 was obtained from Daiichi Pharmaceutical Co. Ltd. (Tokyo, Japan) and Yakult Honsha Co. Ltd. (Tokyo, Japan). The lactone and carboxylate forms of CPT-11 were obtained by dissolving them in 50 mM phosphate buffer at pH 3.0 or 9.0 and leaving them overnight (Chu et al., 1997b). CsA, verapamil, taurocholic acid (TCA), ATP, AMP, creatine phosphate, and creatine phosphokinase were purchased from Sigma (St. Louis, MO). PSC-833 was kindly provided by Novartis (Basel, Switzerland). Unlabeled and 3H-labeled DNP-SG (50.0 μCi/nmol) were synthesized as described previously (Chu et al., 1997a). All other chemicals were commercial products and of analytical grade. Male Sprague-Dawley rats weighing 250 to 300 g were purchased from Charles River Japan Inc. (Kanagawa, Japan).

Uptake Study Using CMVs.

CMVs were prepared from male SD rats as described previously (Chu et al., 1997a). Uptake of the carboxylate or lactone form of CPT-11 was allowed to take place for 2 min at 37°C (Chu et al., 1997a). The total volume of incubation mixture was 20 μl, and the final protein and ATP concentration was 1 mg protein/ml and 5 mM, respectively. CsA or PSC-833 was dissolved in ethanol and diluted to a final concentration with transport buffer (250 mM sucrose, 10 mM Tris/HCl, 10 mM MgCl2, pH7.4, 1000-fold). In the control study, the same concentration of ethanol also was added to the transport medium. The concentration of the carboxylate and lactone forms of CPT-11 in filters and medium was determined by HPLC as described previously (Chu et al., 1997a). To evaluate the effect of several compounds on the uptake of DNP-SG, 1.0 μM [3H]DNP-SG was added to the transport medium. Radioactivity retained on the filter was determined using a liquid scintillation counter (Chu et al., 1997a). The ATP-independent uptake of the substrate was determined in the presence of 5 mM AMP- and ATP-regenerating system. The ATP-dependent uptake was obtained by subtracting the uptake in the presence of AMP from that in the presence of ATP.

Results and Discussion

ATP-dependent uptake of the carboxylate form of CPT-11 at 5 μM, at which the high-affinity component is mainly attributed to the uptake (Chu et al., 1997b), was inhibited significantly by PSC-833, verapamil, and CsA (Fig. 1A), whereas no significant inhibitory effect of PSC-833 and verapamil was observed at 250 μM CPT-11 (Fig. 1B). There was also no inhibitory effect of verapamil on DNP-SG uptake, and only the highest concentration of PSC-833 examined (10 μM) exhibited clear inhibition (Fig. 1C). Thus, verapamil and PSC-833 specifically inhibited the high-affinity component of the carboxylate form of CPT-11, suggesting that the transporter responsible for the high-affinity component may be P-gp. However, possible involvement of mrp family transporters other than cMOAT cannot be ruled out. Of these compounds, verapamil seems to be the only inhibitor that is uniquely associated with P-gp. The present finding also is supported by our recent observation that the carboxylate form of CPT-11 (5 μM) exhibited significant ATP-dependent uptake in membrane vesicles isolated from the KB-C2 cell line, a human epidermoid KB carcinoma-derived cell line that overexpresses P-gp (Chu et al., 1999). Unlike verapamil and PSC-833, CsA inhibited the ATP-dependent uptake of CPT-11 at 250 μM (Fig. 1B). This might result from its similar affinity for P-gp and cMOAT (Böhme et al., 1993). The Ki of PSC-833 for P-gp is much lower than that for cMOAT (0.3 and 29 μM, respectively) (Böhme et al., 1993). Thus, it might be reasonable to assume that its effect on CPT-11 transport at 5 μM could be differentiated from that on CPT-11 transport at 250 μM (Fig. 1). TCA exhibited a minimal inhibitory effect (Fig. 1), suggesting that canalicular bile acid transporter is not responsible for the CPT-11 transport. It is believed that P-gp mainly accepts amphipathic cationic or neutral compounds as substrates (Alexander et al., 1989). Interestingly, our present finding suggests that the carboxylate form of CPT-11, a monovalent anion, is a substrate of both cMOAT and P-gp. It should be noted that topotecan (Sikic et al., 1997), with a structure similar to CPT-11, and estradiol 17-(β-d-glucuronide) (Vore et al., 1996), a well known endogenous substrate of cMOAT, are also substrates of P-gp. Thus, P-gp may accept certain types of anionic compounds and act in coordination with cMOAT to detoxify endogenous compounds and exogenous xenobiotics.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The effect of several compounds on ATP-dependent uptake of the carboxylate form of CPT-11 at substrate concentrations of 5 (A) and 250 μM (B) and of [3H]DNP-SG (C) by rat CMVs.

CMVs were incubated with 5 μM (A) and 250 μM (B) of the carboxylate form of CPT-11 or 1 μM [3H]DNP-SG (C) in the presence of various compounds for 2 min. ATP-dependent uptake was obtained by subtracting the uptake in the presence of 5 mM AMP from that in the presence of 5 mM ATP. Data are the mean ± S.E. of three CMV preparations. *P ≪ .05 and **P ≪ .01, significantly different from controls.

Footnotes

  • Send reprint requests to: Yuichi Sugiyama, Ph.D., Professor and Chair, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: sugiyama{at}seizai.f.u-tokyo.ac.jp

  • This study was supported, in part, by a Grant-in-Aid for Scientific Research provided by the Ministry of Education, Science, and Culture of Japan; a grant for Cancer Research from the Ministry of Health and Welfare of Japan; and CREST (Core Research for Evolutional Science and Technology) of Japan Science and Technology Corporation (to J.S.T.).

  • Abbreviations used are::
    CPT-11
    7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin
    CMVs
    canalicular membrane vesicles
    P-gp
    P-glycoprotein
    cMOAT
    canalicular multispecific organic anion transporter
    DNP-SG
    S-(2,4-dinitrophenyl) glutathione
    CsA
    cyclosporin A
    • Received July 21, 1998.
    • Accepted January 18, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Alexander M,
    2. der Bliek V,
    3. Borst P
    (1989) Multidrug resistance. Adv Cancer Res 52:165–203.
    OpenUrlPubMed
  2. ↵
    1. Böhme M,
    2. Büchler M,
    3. Müller M,
    4. Keppler D
    (1993) Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193–196.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chu XY,
    2. Kato Y,
    3. Niinuma K,
    4. Sudo KI,
    5. Hakusui H,
    6. Sugiyama Y
    (1997a) Multispecific organic anion transporter (cMOAT) is responsible for biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 281:304–314.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Chu XY,
    2. Kato Y,
    3. Sugiyama Y
    (1997b) Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57:1934–1938.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Chu XY,
    2. Suzuki H,
    3. Ueda K,
    4. Kato Y,
    5. Akiyama S,
    6. Sugiyama Y
    (1999) Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 288:735–741.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Fassberg J,
    2. Stella VJ
    (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676–684.
    OpenUrlPubMed
  7. ↵
    1. Gupta E,
    2. Safa AR,
    3. Wang X,
    4. Ratain MJ
    (1996) Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 56:1309–1314.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kaneda N,
    2. Yokokura T
    (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721–1725.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Kojima A,
    2. Shinkai T,
    3. Saijo N
    (1993) Cytogenetic effects of CPT-11 and its active metabolites, SN-38 on human lymphocytes. Jpn J Clin Oncol 23:116–122.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Sikic BI,
    2. Fisher GA,
    3. Lum BL,
    4. Halsey J,
    5. Beketic-Oreskovic L,
    6. Chen G
    (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chem Pharmacol 40:S13–S19.
  11. ↵
    1. Slichenmyer WJ,
    2. Rowinsky EK,
    3. Donehower RC,
    4. Kaufmann SH
    (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 85:271–291.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Vore M,
    2. Hoffman T,
    3. Gosland M
    (1996) ATP-dependent transport of β-estradiol 17-(β-D-glucuronide) in rat canalicular membrane vesicles. Am J Physiol 271:G791–G798.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (4)
Drug Metabolism and Disposition
Vol. 27, Issue 4
1 Apr 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats

Xiao-Yan Chu, Yukio Kato and Yuichi Sugiyama
Drug Metabolism and Disposition April 1, 1999, 27 (4) 440-441;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats

Xiao-Yan Chu, Yukio Kato and Yuichi Sugiyama
Drug Metabolism and Disposition April 1, 1999, 27 (4) 440-441;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics